NIH Rejects Compulsory License For Abbott's Norvir

Law360, New York (August 5, 2004, 12:00 AM EDT) -- A U.S. government agency has rejected calls for a compulsory license for a popular HIV medicine used to boost AIDS drugs, dealing a setback for activists who had hoped to use a little-known law to override a drug maker’s patent rights.

In its ruling, the National Institutes of Health rejected a "march-in petition" filed by Essential Inventions, which urged the NIH to claim control over patent rights to Norvir, a drug sold by Abbott Laboratories. The group asked the NIH to act after Abbott raised the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.